Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display

Pi, Yu; Zhang, Xin; Shi, Junjun; Jin, Zhu; Chen, Wenqing; Zhang, Chenguang; Gao, Weiwei; Zhou, Chunyan; Ao, Yingfang

doi:10.1016/j.biomaterials.2011.05.017

Cited by 94 publications

(99 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…77 Similarly, CAP might not display optimal affinity for OA mouse chondrocytes. Selecting a different ligand through two-step biopanning on explants from OA mice could improve chondrocyte targeting selectivity and therapeutic efficacy of this platform.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy

Bottini

Bhattacharya

Fadeel

et al. 2016

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Non-viral systems based on ligand-conjugated PEI have been recently used by Pi et al to selectively deliver genetic cargo into chondrocytes 77. The authors identified a chondrocyte-homing peptide (CAP, sequence: DWRVIIPPRPSA) by means of a two-step biopanning using synovium and cartilage explants from healthy rabbits.…”

mentioning

confidence: 99%

Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy

Bottini

Bhattacharya

Fadeel

et al. 2016

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

“…26,43,44 Interest in the use of GAMs is also high, 45,46 and research into improving the efficiency and targeting of nonviral vectors continues. Pi et al ., 47 for example, identified peptides that traffic specifically to chondrocytes and enhance transfection when attached to polyethylenimine. Gene delivery for cartilage repair has been reviewed elsewhere.…”

Section: Gene Therapy Progressmentioning

confidence: 99%

Gene therapy approaches to regenerating the musculoskeletal system

2015

View full text Add to dashboard Cite

Injuries to the musculoskeletal system are common, debilitating and expensive. In many cases, healing is imperfect, which leads to chronic impairment. Gene transfer might improve repair and regeneration at sites of injury by enabling the local, sustained and potentially regulated expression of therapeutic gene products; such products include morphogens, growth factors and anti-inflammatory proteins. Proteins produced endogenously as a result of gene transfer are nascent molecules that have undergone post-translational modification. In addition, gene transfer offers particular advantages for the delivery of products with an intracellular site of action, such as transcription factors and noncoding RNAs, and proteins that need to be inserted into a cell compartment, such as a membrane. Transgenes can be delivered by viral or nonviral vectors via in vivo or ex vivo protocols using progenitor or differentiated cells. The first gene transfer clinical trials for osteoarthritis and cartilage repair have already been completed. Various bone-healing protocols are at an advanced stage of development, including studies with large animals, and human trials are envisaged. Other applications in the repair and regeneration of skeletal muscle, intervertebral disc, meniscus, ligament and tendon are in preclinical development. In addition to scientific, medical and safety considerations, clinical translation is constrained by social, financial and logistical issues.

show abstract

“…Recently, a chondrocyte-affinity peptide (CAP), was identified via affinity peptide biopanning 66 . Gene vehicles can be modified by this peptide to allow for specific transfection into chondrocytes.…”

Section: Articular Cartilage Targetingmentioning

confidence: 99%

Osteoarthritis: Pathology, Mouse Models, and Nanoparticle Injectable Systems for Targeted Treatment

et al. 2016

View full text Add to dashboard Cite

Osteoarthritis (OA) is a progressive, degenerative disease of articulating joints that not only affects the elderly, but also involves younger, more active individuals with prolonged participation in high physical-demand activities. Thus, effective therapies that are easy to adopt clinically are critical in limiting the societal burden associated with OA. This review is focused on intra-articular injectable regimens and provides a comprehensive look at existing in vivo models of OA that might be suitable for developing, testing, and finding a cure for OA by intra-articular injections. We first discuss the pathology, molecular mechanisms responsible for the initiation and progression of OA, and challenges associated with disease-specific targeting of OA. We proceed to discuss available animal models of OA and provide a detailed perspective on the use of mouse models in studies of experimental OA. We finally provide a closer look at intra-articular injectable treatments for OA, focusing on biomaterials-based nanoparticles, and provide a comprehensive overview of the various nanometer-size ranges studied.

show abstract

Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display

Cited by 94 publications

References 26 publications

Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy

Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy

Gene therapy approaches to regenerating the musculoskeletal system

Osteoarthritis: Pathology, Mouse Models, and Nanoparticle Injectable Systems for Targeted Treatment

Contact Info

Product

Resources

About